Free Trial

Opus Genetics (IRD) News Today

$0.98 -0.01 (-0.87%)
(As of 12/20/2024 05:31 PM ET)
Opus Genetics receives FDA agreement under SPA for Phase 3 trial of APX3330
Opus Genetics, Inc. (IRD)
Get Opus Genetics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IRD and its competitors with MarketBeat's FREE daily newsletter.

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Register for the FREE Workshop Now & get $10 in Bitcoin

IRD Media Mentions By Week

IRD Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

IRD
News Sentiment

0.70

0.60

Average
Medical
News Sentiment

IRD News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

IRD Articles
This Week

6

1

IRD Articles
Average Week

Get Opus Genetics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IRD and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:IRD) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners